We are live on ! Find out more
COGT icon

Cogent Biosciences
COGT

48 hedge funds and large institutions have $158M invested in Cogent Biosciences in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

17% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 12

9% more funds holding

Funds holding: 44 → 48 (+4)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.07% less ownership

Funds ownership: 12.88% → 12.82% (-0.07%)

26% less capital invested

Capital invested by funds: $212M → $158M (-$54.5M)

Holders
48
Holders Change
+4
Holders Change %
+9.09%
% of All Funds
1.1%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
10
Increased
14
Reduced
12
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$989K
2
CI
Cowen Inc
New York
+$970K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$720K
4
State Street
State Street
Massachusetts
+$630K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$434K

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.15M
2
PIM
Platinum Investment Management
Australia
-$695K
3
Jennison Associates
Jennison Associates
New York
-$638K
4
BlackRock
BlackRock
New York
-$635K
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$576K
Name Holding Trade Value Shares
Change 		Change in
Stake
TDC
51
Thompson Davis & Co
Virginia
– -$12K -217 Closed
PIA
52
Piedmont Investment Advisors
North Carolina
– -$1K -16 Closed
FIA
53
FNY Investment Advisers
New York
– +$169 +3 New
1 2
3

COGT Hedge Fund Activity: Q3 2018 in Review

48 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q3 2018, worth a combined $158M — down 26% from $212M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new COGT positions and 6 closed out — a net gain of 4 holders — while 14 added to existing stakes and 12 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $989K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $2.15M sold.

  • 48 institutional investors held Cogent Biosciences (COGT) as of Q3 2018, up from 44 in Q2 2018.
  • Funds reported $158M of Cogent Biosciences stock for Q3 2018, down 26% quarter-over-quarter.
  • 10 funds opened new Cogent Biosciences positions in Q3 2018 and 6 closed out, a net change of +4 holders.
  • The largest Cogent Biosciences buyer in Q3 2018 was Renaissance Technologies, an estimated $989K added.
  • The largest Cogent Biosciences seller in Q3 2018 was Point72 Asset Management, an estimated $2.15M sold.

Based on aggregated 13F filings for Q3 2018.